Clinical trial
Assessment of Tumor Perfusion Changes in Response to Pazopanib in Renal Cell Carcinoma
NCT01221506 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Assessment of Tumor Perfusion Changes in Response to Pazopanib in Renal Cell Carcinoma
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2010
- Completion date
- April 30, 2019
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.